Skip to main content
OpenTrials
Completed

NCT Number: NCT00314171

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older
  • Diagnosis of open-angle glaucoma or ocular hypertension
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

  • Under 18
  • Pregnant
  • Other protocol-defined exclusion criteria may apply

Treatment and study plan

Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension

Drug

One drop in the study eye(s) twice daily for 12 months

Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)

Drug

One drop in the study eye(s) twice daily for 12 months

Other names: COSOPT

Primary outcomes

  1. Mean IOP

Secondary outcomes

  1. Percent patients with IOP < 18 mmHg

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Apr 13, 2006
Registry last updated
Nov 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.